M&A Boom Seen in 2014 as Drug Hunt Spurs Biotech Deals

Health-care companies with deep pockets and shallow product pipelines are poised for a busy year of acquisitions, with biotechnology firms likely to be among the most prominent targets even as they trade at record highs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.